My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 556

    1.

    Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

    Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ; Viral Activation Transfusion Study Investigators.

    Ann Intern Med. 2001 Jul 3;135(1):17-26.PMID: 11434728 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial.

    Collier AC, Kalish LA, Busch MP, Gernsheimer T, Assmann SF, Lane TA, Asmuth DM, Lederman MM, Murphy EL, Kumar P, Kelley M, Flanigan TP, McMahon DK, Sacks HS, Kennedy MS, Holland PV; Viral Activation Transfusion Study Group.

    JAMA. 2001 Mar 28;285(12):1592-601.PMID: 11268267 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

    Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

    Ann Intern Med. 2004 Feb 17;140(4):256-64.PMID: 14970148 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    [Predictors of progression and death in patients with advanced HIV infection in the era of highly active antiretroviral therapy]

    Reus S, Portilla J, Gimeno A, Sánchez-Payá J, García-Henarejos JA, Martínez-Madrid O, Usó J, Roca B, Galindo MJ, López-Aldeguer J.

    Enferm Infecc Microbiol Clin. 2004 Mar;22(3):142-9. Spanish. PMID: 14987534 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

    Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

    Pediatrics. 2002 Feb;109(2):E25.PMID: 11826235 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.

    Salmon-Céron D, Mazeron MC, Chaput S, Boukli N, Senechal B, Houhou N, Katlama C, Matheron S, Fillet AM, Gozlan J, Leport C, Jeantils V, Freymuth F, Costagliola D.

    AIDS. 2000 May 26;14(8):1041-9.PMID: 10853987 [PubMed - indexed for MEDLINE]Related articles

    7.

    Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.

    Gandhi T, Wei W, Amin K, Kazanjian P.

    Clin Infect Dis. 2006 Mar 15;42(6):878-84. Epub 2006 Feb 8.PMID: 16477568 [PubMed - indexed for MEDLINE]Related articles

    8.

    Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART.

    Gerna G, Piccinini G, Genini E, Percivalle E, Zavattoni M, Lilleri D, Testa L, Comolli G, Maserati R, Baldanti F, Maccario R, Monforte AD, Revello MG.

    J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):320-31.PMID: 11707667 [PubMed - indexed for MEDLINE]Related articles

    9.

    Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies.

    Wohl DA, Zeng D, Stewart P, Glomb N, Alcorn T, Jones S, Handy J, Fiscus S, Weinberg A, Gowda D, van der Horst C.

    J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):538-44.PMID: 15793363 [PubMed - indexed for MEDLINE]Related articles

    10.

    Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease.

    Verbraak FD, Boom R, Wertheim-van Dillen PM, van den Horn GJ, Kijlstra A, de Smet MD.

    Br J Ophthalmol. 1999 Oct;83(10):1186-9.PMID: 10502584 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.

    Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS.

    Ann Intern Med. 2003 Nov 18;139(10):810-6.PMID: 14623618 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV infected patients: natural history and clinical predictors.

    Lin DY, Warren JF, Lazzeroni LC, Wolitz RA, Mansour SE.

    Retina. 2002 Jun;22(3):268-77.PMID: 12055458 [PubMed - indexed for MEDLINE]Related articles

    13.

    Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy.

    Jouan M, Savès M, Tubiana R, Carcelain G, Cassoux N, Aubron-Olivier C, Fillet AM, Nciri M, Sénéchal B, Chêne G, Tural C, Lasry S, Autran B, Katlama C; RESTIMOP study team.

    AIDS. 2001 Jan 5;15(1):23-31.PMID: 11192865 [PubMed - indexed for MEDLINE]Related articles

    14.

    Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.

    Hung CC, Chen MY, Hsieh SM, Hsiao CF, Sheng WH, Chang SC.

    Vaccine. 2004 May 7;22(15-16):2006-12.PMID: 15121313 [PubMed - indexed for MEDLINE]Related articles

    15.

    Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.

    Arici C, Ripamonti D, Ravasio V, Maggiolo F, Rizzi M, Finazzi MG, Suter F.

    Int J STD AIDS. 2001 Sep;12(9):573-81.PMID: 11516366 [PubMed - indexed for MEDLINE]Related articles

    16.

    Clinical spectrum, morbidity, and mortality of acquired immunodeficiency syndrome in Taiwan: a 5-year prospective study.

    Hung CC, Chen MY, Hsieh SM, Sheng WH, Chang SC.

    J Acquir Immune Defic Syndr. 2000 Aug 1;24(4):378-85.PMID: 11015155 [PubMed - indexed for MEDLINE]Related articles

    17.

    Predictors of AIDS-defining events among advanced naïve patients after HAART.

    Torti C, Lapadula G, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Pietro MD, Migliorino G, Quiros-Roldan E, Ladisa N, Sighinolfi L, Gatti F, Carosi G; Italian MASTER Cohort.

    HIV Clin Trials. 2007 May-Jun;8(3):112-20.PMID: 17621458 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study.

    Mitchell SM, Membrey WL, Youle MS, Obi A, Worrell S, Gazzard BG.

    Br J Ophthalmol. 1999 Jun;83(6):652-5.PMID: 10340970 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.

    Lohse N, Kronborg G, Gerstoft J, Larsen CS, Pedersen G, Pedersen C, Sørensen HT, Obel N.

    Clin Infect Dis. 2006 Jan 1;42(1):136-44. Epub 2005 Nov 30.PMID: 16323104 [PubMed - indexed for MEDLINE]Related articles

    20.

    The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.

    Miller V, Sabin CA, Phillips AN, Rottmann C, Rabenau H, Weidmann E, Rickerts V, Findhammer S, Helm EB, Staszewski S.

    AIDS. 2000 Sep 29;14(14):2129-36.PMID: 11061654 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity